SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order
Sun Pharma - Global Specialty Sales To Get A Boost From Addition Of Australian Geography: DRChoksey
Sun Pharma has announced that the Australian Therapeutic Goods Administration has granted regulatory approval for Winlevi (clascoterone cream 1%). SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release Sun Pharma announces approval of Winlevi in Australia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation -March 2024
Buy Sun Pharmaceutical Industries; target of Rs 1727: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1727 in its research report dated March 11, 2024.
Sun Pharma Recalls 55,000 Bottles Of Gout Drug From U.S. Market Due To Manufacturing Norms Violation
Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment, the U.S. FDA stated. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of Share Certificates
Sun Pharma hits 52- week high on USFDA all-clear to Ankleshwar unit
The USFDA classified the unit as No Action Indicated, paving the way for manufacturing and export from the plant, a CNBC Awaaz report said